Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - phenoxymethylpenicillin potassium 28.284 mg/ml equivalent to 25 mg/ml phenoxymethylpenicillin.;  ;   - granules for oral solution - 125 mg/5ml - active: phenoxymethylpenicillin potassium 28.284 mg/ml equivalent to 25 mg/ml phenoxymethylpenicillin.     excipient: orange 175-78-8 orange flavour j1978 10814413 saccharin sodium sodium benzoate sucrose as caster sugar. - treatment of mild to moderately severe infections caused by penicillin-sensitive organisms. the following infections will usually respond to an adequate dosage of penicillin.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - phenoxymethylpenicillin potassium 56.568 mg/ml equivalent to 50 mg/ml phenoxymethylpenicillin;  ;   - granules for oral solution - 250 mg/5ml - active: phenoxymethylpenicillin potassium 56.568 mg/ml equivalent to 50 mg/ml phenoxymethylpenicillin     excipient: orange 175-78-8 orange flavour j1978 10814413 saccharin sodium sodium benzoate sucrose as caster sugar. - treatment of mild to moderately severe infections caused by penicillin-sensitive organisms. the following infections will usually respond to an adequate dosage of penicillin.

Royaume-Uni - anglais - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - phenoxymethylpenicillin potassium - oral tablet - 250mg

Australie - anglais - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - phenoxymethylpenicillin benzathine, quantity: 40.27 mg/ml (equivalent: phenoxymethylpenicillin, qty 30 mg/ml) - oral liquid, suspension - excipient ingredients: sodium propyl hydroxybenzoate; sodium methyl hydroxybenzoate; butylated hydroxyanisole; polysorbate 80; xanthan gum; sucrose; purified water; sodium citrate dihydrate; potassium sorbate; citric acid; flavour - treatment of mild to moderately severe infections due to penicillin sensitive staphylococci, pneumococci, gonococci and haemolytic streptococci infections. therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. for prophylactic use in recurrent streptococcal infections including the prevention of recurrence following rheumatic fever and/or sydenham's chorea and to prevent bacterial endocarditis in patients with rheumatic fever and/or congenital heart disease who are about to undergo dental or upper respiratory surgery or instrumentation. note: oral penicillin should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower intestinal tract surgery, sigmoidoscopy or complications of childbirth.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - phenoxymethylpenicillin -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - phenoxymethylpenicillin -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - phenoxymethylpenicillin potassium -

Malte - anglais - Medicines Authority

central procurement & supplies unit - phenoxymethylpenicillin potassium - powder for oral solution - phenoxymethylpenicillin potassium 125 milligram(s)/5 millilitre - antibacterials for systemic use

Malte - anglais - Medicines Authority

cherubino limited - phenoxymethylpenicillin potassium - tablet - phenoxymethylpenicillin potassium 280 mg - antibacterials for systemic use

Australie - anglais - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - phenoxymethylpenicillin potassium, quantity: 560 mg (equivalent: phenoxymethylpenicillin, qty 500 mg) - tablet, film coated - excipient ingredients: maize starch; magnesium stearate; calcium hydrogen phosphate dihydrate; microcrystalline cellulose; titanium dioxide; vanillin; quinoline yellow; purified talc; xanthan gum; polyvinyl alcohol; lecithin; hypromellose; macrogol 6000 - treatment of mild to moderately severe infections caused by penicillin sensitive staphylococci, pneumococci, gonococci and haemolytic streptococci infections. therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. for prophylactic use in recurrent streptococcal infections including the prevention of recurrence following rheumatic fever and/or sydenham?s chorea and to prevent bacterial endocarditis in patients with rheumatic fever and/or congenital heart disease who are about to undergo dental or upper respiratory surgery or instrumentation. note: oral penicillin should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower intestinal tract surgery, sigmoidoscopy or childbirth.